The present disclosure is directed generally to methods for characterizing response to one or more therapies in patients with clinically apparent cancer, or recurrence of disease in treated cancer patients with no clinically apparent cancer. Also disclosed are methods for detecting and/or treating a cancer using allele imbalance and chromosomal instability.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
2.
Targeting the PVR axis using CAR T cell therapy and combinations
Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3□ segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Promoting public interest and awareness of the causes, treatment and prevention of cancer Educational services, namely, conducting programs, seminars, lectures and workshops in the field of cancer awareness
4.
COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS AGAINST CLAUDIN 6
Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a Claudin 6 (CLDN6) antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4+ T cells, CD8+ T cells, and progenitor cells, such as hematopoietic stem cells. The modified cells are capable of direct and indirect recognition of a cancer ell expressing a CLDN6 antigen by human leukocyte antigen (HLA) class I and II restricted binding of the TCR to the CLDN6 antigen expressed by the cancer cell, with or without presentation of the antigen by antigen presenting cells. Also included is a method for prophylaxis and/or therapy of cancer by administering modified cells that express a recombinant TCR that binds to CLDN6.
Various implementations include an in vivo tissue deconstruction system. The system includes an adapter, a deconstruction sack, and a circulation catheter. The adapter has a first end, a second end, and an adapter opening extending from the first end to the second end. The deconstruction sack includes a fluid-impermeable sheet, an inner volume, and a mouth providing access to the inner volume. The deconstruction sack is movable from a collapsed configuration to an expanded configuration. The mouth of the deconstruction sack is sealingly couplable to the adapter. The circulation catheter includes an irrigation conduit and a drainage conduit. The circulation catheter is disposed within the adapter opening and the inner volume of the deconstruction sack. The irrigation conduit of the circulation catheter is fluidically couplable to a supply of deconstruction fluid such that the inner volume of the deconstruction sack is in fluid communication with the supply of deconstruction fluid.
The present disclosure relates to dual DNA-based and RNA-based next generation sequencing assays, comprising a DNA component comprising an oligonucleotide and a detection probe targeting DNA isolated from the hematological neoplasm and an RNA component comprising oligonucleotide and a detection probe targeting RNA isolated from the hematological neoplasm, as well as the treatment of hematological neoplasms.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
7.
IRG Blockade to Armor CAR T Cells Against Myeloid Dysfunction
Disclosed herein are methods and compositions relating to the resistance of adoptive immunotherapy caused by the induction of iNOS in tumor associated macrophage. In one aspect, disclosed herein are methods of methods of treating, inhibiting, reducing, decreasing, ameliorating, and/or preventing a cancer and/or metastasis (such as, for example large B cell lymphoma) in a subject comprising administering to the subject an adoptive immune cell immunotherapy (including, but not limited to administration of chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, tumor infiltrating lymphocytes (TILs)) and an agent that blocks dysregulation of the citric acid cycle (such as, for example, an agent that inhibits inducible nitric oxide synthase (iNOS) and/or an agent that inhibits immune responsive gene 1 (IRG1)) or administering to the subject an adoptive immune cell immunotherapy (including, but not limited to administration of chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, tumor infiltrating lymphocytes (TILs)) wherein the immune cell has been modified to disrupt expression of IRG1.
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
promoting awareness, to the public and to people who study and treat cancer, as to the causes, treatment and prevention of cancer conducting research into the causes, treatment and prevention of cancer medical services directed toward providing care to prospective and actual cancer patients
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, videos on the causes and treatments of adult and pediatric cancer, psychosocial aspects of the effects of adult and pediatric cancer in self or loved ones and distribution of educational, support and course materials in connection therewith; audio recording and production
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
[ Promoting public awareness of the causes of cancer, cancer treatments, and methods of preventing cancer ] Conducting medical and scientific research in the field of cancer, causes of cancer and cancer treatment, diagnosis and prevention Medical services in the field of cancer
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Promoting awareness to the public and to the people who study cancer, as to the causes, treatment and prevention of cancer Charitable fundraising services Educational services, namely, conducting seminars, workshops, classes and courses of instruction about the causes and treatments of cancer, psychosocial aspects of the effects of cancer in self or loved ones, and the potential careers in science and health related professions
36 - Services financiers, assurances et affaires immobilières
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Promoting the awareness to the public and to the people who study cancer, as to the causes, treatment and prevention of cancer Charitable fundraising services Educational services, namely, conducting seminars, workshops, classes and courses of instruction about the causes and treatments of cancer, psychosocial aspects of the effects of cancer in self or loved ones and the potential careers in science and health-related professions
